Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NC-6300 |
Synonyms | |
Therapy Description |
Nanoparticle Epirubicin (NC-6300) consists of a pH-sensitive linker, polymer-bound epirubicin that forms a micellar structure, potentially resulting in increased anti-tumor activity and decreased toxicity (PMID: 23495762, PMID: 28054329, PMID: 32381487). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NC-6300 | K-912|Nanoparticle Epirubicin | Nanoparticle Epirubicin (NC-6300) consists of a pH-sensitive linker, polymer-bound epirubicin that forms a micellar structure, potentially resulting in increased anti-tumor activity and decreased toxicity (PMID: 23495762, PMID: 28054329, PMID: 32381487). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03168061 | Phase Ib/II | NC-6300 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | Unknown status | USA | 0 |